Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriPRIL CAR
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TriPRIL CAR is an investigational chimeric antigen receptor T cell (CAR-T) therapy that uses a rationally designed trimeric APRIL-based binding domain to direct patient-derived T cells against multiple myeloma cells. The CAR targets both B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor (TACI), two TNFR superfamily members highly expressed on myeloma cells. This dual-targeted approach aims to overcome resistance stemming from single-antigen loss (antigen escape) and to expand efficacy for relapsed or refractory multiple myeloma. TriPRIL’s fully human construct also reduces immunogenicity and potential for antimurine immune rejection. TriPRIL CAR T Cells are produced via a rapid manufacturing process and are currently in early clinical testing, with Massachusetts General Hospital and King's College London noted as key development sites[1][2][3][4][5][6].
- Brand names
- TriPRIL CAR
- Other names
- TriPRIL CAR T CellsAutologous Anti-BCMA/Anti-TACI Trimeric APRIL-based CAR-T CellsAutologous BCMA/TACI-targeted Trimeric APRIL-based CAR T Cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on TriPRIL CAR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriPRIL CAR.